TrialThe Lancet. Oncology2025

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

Cathalijne C B Post et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.